Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (780)	1/16/2006 9:08:08 AM
From: sammaster	Read Replies (2) of 946

so because the initial trial was not set up to show non-inferiority, they cannot file for it based on that data..right? i guess if they get it approved for women through its estrogen trial, then doctors may choose to use it "off label" if they feel it offers same efficacy but decreased side effects for their patients? just trying to get a handle on number of possible patients that may be treated if fda approves the "estrogen theory" trial. they stated that 80k women a year are diagnosed with lung cancer.... plus ? "off label" male use due to decreased side effects = ??? total

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next